Overview of the Management of COVID-19 Efficacy and Doubts

Coronavirus disease 2019 (COVID-19) is defined as an illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2. It was first identified during an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China.Management of COVID-19 is still unspecific as there are no vaccine orspecific antiviral drugs areavailable for its treatment. This paper reviewsthemanagement efficacy and doubt of COVID-19.Methods: A comprehensive search from relevant literatures, World Health Organization (W.H.O), Centre for Disease Control and prevention (CDC) official websites and announcements was performed between 1 March2020 to 10:30 am 22 April 2020 (Nigerian time). A latest summary of 2019-nCoV and the current outbreak was drawn.Conclusion: The covid-19 pandemic is spreading rapidly and several researchers are making efforts to discover drugs for its treatment. Chloroquine phosphate, vaccines and other forms of management strategies have been employed. However, preventive measureslike social distancing, washing of handswith soap and water, wearing of face masks and psychosocial treatment should be adopted while waiting for pharmacological treatments.

The Modified Overt Aggression Scale: How Valid in this Environment?

Background:The Modified Overt Aggression Scale (MOAS) has been validated for use in the study of aggression in the developed world; unlike in the undeveloped world. The aim of this study therefore is to ascertain the discriminant validity of the MOAS for use in this part of the world using psychiatric in-patients at the Jos University Teaching Hospital. Methodology: Forty aggressive psychiatric patients and 40 non-aggressive healthy subjects were randomly selected for this study. The psychiatric patients were enlisted after fulfilling the ICD-10 (World Health Organization; 1993) criteria for a specific clinical diagnosis. The 40 non-aggressive subjects were mainly medical students and hospital staff. The MOAS was subsequently used to assess aggression in the entire cohort.Results: The males had higher mean global weighted score than the females in both the aggressive and nonaggressive categories. The mean global weighted scores of the aggressive and non-aggressive categories were 13.70+ 7.25 and 0.65 + 1.01 respectively. The difference in means is statistically significant; hence the MOAS has discriminant validity. Conclusion: Therefore; the modified overt aggression scale is a valid instrument in this environment for the study of aggression

The Modified Overt Aggression Scale: How Valid in this Environment?

Background:The Modified Overt Aggression Scale (MOAS) has been validated for use in the study of aggression in the developed world; unlike in the undeveloped world. The aim of this study therefore is to ascertain the discriminant validity of the MOAS for use in this part of the world using psychiatric in-patients at the Jos University Teaching Hospital. Methodology: Forty aggressive psychiatric patients and 40 non-aggressive healthy subjects were randomly selected for this study. The psychiatric patients were enlisted after fulfilling the ICD-10 (World Health Organization; 1993) criteria for a specific clinical diagnosis. The 40 non-aggressive subjects were mainly medical students and hospital staff. The MOAS was subsequently used to assess aggression in the entire cohort.Results: The males had higher mean global weighted score than the females in both the aggressive and nonaggressive categories. The mean global weighted scores of the aggressive and non-aggressive categories were 13.70+ 7.25 and 0.65 + 1.01 respectively. The difference in means is statistically significant; hence the MOAS has discriminant validity. Conclusion: Therefore; the modified overt aggression scale is a valid instrument in this environment for the study of aggression